The influence of myeloid-derived suppressor cells on angiogenesis and tumor growth after cancer surgery
- PMID: 26756887
- DOI: 10.1002/ijc.29998
The influence of myeloid-derived suppressor cells on angiogenesis and tumor growth after cancer surgery
Abstract
While myeloid-derived suppressor cells (MDSCs) have been reported to participate in the promotion of angiogenesis and tumor growth, little is known about their presence and function during perioperative period. Here, we demonstrated that human MDSCs expressing CD11b(+), CD33(+) and HLA-DR(-) significantly increased in lung cancer patients after thoracotomy. CD11b(+) CD33(+) HLA-DR(-) MDSCs isolated 24 hr after surgery from lung cancer patients were more efficient in promoting angiogenesis and tumor growth than MDSCs isolated before surgical operation in allograft tumor model. In addition, CD11b(+) CD33(+) HLA-DR(-) MDSCs produced high levels of MMP-9. Using an experimental lung metastasis mouse model, we demonstrated that the numbers of metastases on lung surface and Gr-1(+) CD11b(+) MDSCs at postoperative period were enhanced in proportion to the degree of surgical manipulation. We also examined that syngeneic bone marrow mesenchymal stem cells (BMSCs) significantly inhibited the induction and proliferation of Gr-1(+) CD11b(+) MDSCs and further prevented lung metastasis formation in the mice undergoing laparotomy. Taken together, our results suggest that postoperatively induced MDSCs were qualified with potent proangiogenic and tumor-promotive ability and this cell population should be considered as a target for preventing postoperative tumor metastasis.
Keywords: bone marrow mesenchymal stem cells; lung cancer; metastasis; myeloid-derived suppressor cells; perioperative period.
© 2016 UICC.
Similar articles
-
A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.J Immunol Res. 2014;2014:659294. doi: 10.1155/2014/659294. Epub 2014 Nov 11. J Immunol Res. 2014. PMID: 25436215 Free PMC article.
-
Surgery-induced monocytic myeloid-derived suppressor cells expand regulatory T cells in lung cancer.Oncotarget. 2017 Mar 7;8(10):17050-17058. doi: 10.18632/oncotarget.14991. Oncotarget. 2017. PMID: 28178645 Free PMC article.
-
[The number of myeloid-derived suppressor cells in the peripheral blood and tumor tissues in patients with gastric cancer and its clinical significance].Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2014 Jul;30(7):740-3. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2014. PMID: 25001941 Chinese.
-
Regulation of tumor metastasis by myeloid-derived suppressor cells.Annu Rev Med. 2015;66:97-110. doi: 10.1146/annurev-med-051013-052304. Epub 2014 Oct 9. Annu Rev Med. 2015. PMID: 25341012 Free PMC article. Review.
-
Roles of Myeloid-Derived Suppressor Cells in Cancer Metastasis: Immunosuppression and Beyond.Arch Immunol Ther Exp (Warsz). 2019 Apr;67(2):89-102. doi: 10.1007/s00005-018-0531-9. Epub 2018 Nov 2. Arch Immunol Ther Exp (Warsz). 2019. PMID: 30386868 Review.
Cited by
-
Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy.Front Immunol. 2023 Dec 15;14:1291530. doi: 10.3389/fimmu.2023.1291530. eCollection 2023. Front Immunol. 2023. PMID: 38193080 Free PMC article. Review.
-
Cancer-Associated Fibroblast-Induced Remodeling of Tumor Microenvironment in Recurrent Bladder Cancer.Adv Sci (Weinh). 2023 Nov;10(31):e2303230. doi: 10.1002/advs.202303230. Epub 2023 Sep 24. Adv Sci (Weinh). 2023. PMID: 37743226 Free PMC article.
-
The recent progress of myeloid-derived suppressor cell and its targeted therapies in cancers.MedComm (2020). 2023 Aug 2;4(4):e323. doi: 10.1002/mco2.323. eCollection 2023 Aug. MedComm (2020). 2023. PMID: 37547175 Free PMC article. Review.
-
Perioperative Inflammatory Response and Cancer Recurrence in Lung Cancer Surgery: A Narrative Review.Front Surg. 2022 Jul 11;9:888630. doi: 10.3389/fsurg.2022.888630. eCollection 2022. Front Surg. 2022. PMID: 35898583 Free PMC article. Review.
-
Nano Drug Delivery System for Tumor Immunotherapy: Next-Generation Therapeutics.Front Oncol. 2022 May 19;12:864301. doi: 10.3389/fonc.2022.864301. eCollection 2022. Front Oncol. 2022. PMID: 35664731 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
